Search Results - "Scholz, Catherine Rose"

Patient reported abdominal pain as a surrogate of the clinical benefit of tipifarnib in pancreatic cancer patients by Gualberto, Antonio, Scholz, Catherine Rose, Van Cutsem, Eric

“…Abstract only 275 Background: Tumor CXCL12 expression identifies patients who may benefit from tipifarnib therapy. In pancreatic cancer, CXCL12 is known to…”
Get full text

Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations by Ho, Alan Loh, Hanna, Glenn J., Scholz, Catherine Rose, Gualberto, Antonio, Park, Se Hoon

“…Abstract only 6504 Background: HRAS is a proto-oncogene overexpressed and mutated in some human carcinomas. Tipifarnib is a potent and highly selective…”
Get full text

Tipifarnib, a farnesyltransferase inhibitor, for metastatic urothelial carcinoma harboring HRAS mutations by Lee, Jiyun, Kim, Hana, Gualberto, Antonio, Scholz, Catherine Rose, Park, Se Hoon

“…Abstract only 5086 Background: Tipifarnib is a farnesyltransferase inhibitor known to block RAS signaling and attenuate cancer cell proliferation. We tested…”
Get full text

The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN) by Haddad, Robert I., Harrington, Kevin Joseph, Licitra, Lisa F., Psyrri, Amanda, Saba, Nabil F., Rajicic, Natasa, Balsara, Binaifer, Kurman, Michael R., Scholz, Catherine Rose, Gualberto, Antonio, Ho, Alan Loh

“…Abstract only TPS6593 Background: HRAS mutations define a unique molecular subset of ~ 5% of HNSCC. Evidence suggests that these tumors respond poorly to…”
Get full text

Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer by Johnston, Stephen R. D., Pluard, Timothy J., Wang, Judy S., Hamilton, Erika P., Juric, Dejan, Scholz, Catherine Rose, Hnitecki, Elizabeth, Gao, Lei, Cantagallo, Lisa, Korpal, Manav, Destenaves, Benoit, Xiao, Jianjun Alan, Zhang, Zhaojie, Pipas, J. Marc Marc, Yu, Lihua, Sahmoud, Tarek, Gualberto, Antonio

“…Abstract only e13025 Background: H3B-6545, a highly Selective ERα Covalent Antagonist (SERCA), inactivates both wild-type and mutant ERα by targeting cysteine…”
Get full text

An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck by Ho, Alan Loh, Chau, Nicole Grace, Wong, Deborah Jean Lee, Cabanillas, Maria E., Bauman, Jessica Ruth, Bible, Keith Christopher, Brose, Marcia S., Calvo, Emiliano, Boni, Valentina, Burrows, Francis, Melvin, Carrie L., Scholz, Catherine Rose, Gualberto, Antonio

“…Abstract only TPS2618 Background: Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase (FT). FT catalyzes the post-translational…”
Get full text